This prospective study aimed to assess the efficacy of [18F]AlF-FAPI-RGD, a dual-targeting heterodimer tracer that focuses on fibroblast activation protein (FAP) and integrin αvβ3, through PET/CT imaging for evaluating disease activity and response to treatment in RA. The gene discussed is FAP; the disease is rheumatoid arthritis.